Second Cancer Incidence and Cause‐Specific Mortality in Primary Gastrointestinal Non‐Hodgkin Lymphoma Survivors: A Population‐Based Cohort Study
Open Access
- 20 November 2025
- journal article
- Published by Wiley in Cancer Medicine
- Vol. 14 (22) , e71405
Abstract
Background: Therapeutic advances in primary gastrointestinal non‐Hodgkin lymphoma (PGI‐NHL) have improved patient prognosis but also raised concerns regarding long‐term health outcomes. This study assesses patterns of second primary cancers (SPCs) and cause‐specific mortality in PGI‐NHL survivors. Methods: A total of 7556 six‐month survivors of PGI‐NHL diagnosed between 1975 and 2015 were identified from the SEER database. SPC risks were evaluated using overall and site‐specific standardized incidence ratios (SIRs) and absolute excess risks (AERs) relative to the US general population. Cause‐specific mortality was assessed through proportional death distribution, the Fine–Gray competing risk regression model, standardized mortality ratios (SMRs), and AERs. Results: During 75,914 person‐years of follow‐up, 1245 patients developed 1412 SPCs (SIR = 1.20, 95% CI = 1.14–1.27). Significantly elevated SIRs were observed for solid tumors (SIR = 1.16, 95% CI = 1.10–1.23) and hematolymphoid malignancies (SIR = 1.82, 95% CI = 1.49–2.19). Survivors with over 20 years of follow‐up faced increased risks of oral cavity and pharyngeal cancers (SIR = 2.76, 95% CI = 1.11–5.69), gastric cancer (SIR = 3.12, 95% CI = 1.15–6.80), pancreatic cancer (SIR = 2.40, 95% CI = 1.10–4.55), and leukemia (SIR = 2.57, 95% CI = 1.17–4.87). The risk of developing SPCs decreased with increasing age at PGI‐NHL diagnosis. Patients receiving combined chemoradiotherapy exhibited the highest overall SPC risk (SIR = 1.32, 95% CI = 1.09–1.58), particularly for gastric cancer (SIR = 8.20, 95% CI = 4.59–13.53) and pancreatic cancer (SIR = 3.15, 95% CI = 1.44–5.98). A total of 4949 deaths occurred (SMR = 1.80, 95% CI = 1.75–1.85), with excess mortality persisting beyond two decades. The cumulative incidence of all‐cause mortality was 28.9% at 5 years, 45.8% at 10 years, and 69.1% at 20 years post‐diagnosis. Non‐cancer causes posed a significant risk, with higher mortality from infections (SMR = 2.48, 95% CI = 2.22–2.76), chronic liver diseases (SMR = 1.72, 95% CI = 1.20–2.38), and benign/in situ neoplasms (SMR = 1.62, 95% CI = 1.05–2.38). Conclusions: PGI‐NHL survivors face elevated long‐term SPC risk, particularly after chemoradiotherapy and in younger patients. Excess risks for both SPCs and mortality persist beyond two decades, necessitating lifelong, risk‐adapted survivorship care that includes cancer surveillance, infection prevention, and chronic comorbidity management.Keywords
Funding Information
- National Natural Science Foundation of China (82171890)
This publication has 51 references indexed in Scilit:
- Risk of second cancer after treatment of aggressive non-Hodgkin's lymphoma; an EORTC cohort study.2006
- Second primary cancers among 109 000 cases of non-Hodgkin's lymphomaBritish Journal of Cancer, 2005
- Clinical Activity of Rituximab in Gastric Marginal Zone Non-Hodgkin's Lymphoma Resistant to or Not Eligible for Anti–Helicobacter Pylori TherapyJournal of Clinical Oncology, 2005
- RituximabDrugs, 2003
- Primary Gastrointestinal Non-Hodgkin’s Lymphoma: I. Anatomic and Histologic Distribution, Clinical Features, and Survival Data of 371 Patients Registered in the German Multicenter Study GIT NHL 01/92Journal of Clinical Oncology, 2001
- Synchronous gastric adenocarcinoma and mucosa-associated lymphoid tissue lymphoma in association with Helicobacter pylori infection: comparing reported cases between the East and WestAmerican Journal of Gastroenterology, 2001
- Incidence of second neoplasms in patients with MALT lymphoma: No increase in risk above the background populationAnnals of Oncology, 1999
- Other Cancers in Patients with Gastric Malt LymphomaLeukemia & Lymphoma, 1999
- Additional neoplasms and HCV infection in low‐grade lymphoma of MALT typeBritish Journal of Haematology, 1996
- Overall evaluations of carcinogenicity: an updating of IARC Monographs volumes 1 to 42.1987